Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 23 for “"programmed death ligand-1"”.
-
PROGRAMMED DEATH LIGAND 1 (PD-L1) IMMUNE CHECKPOINT-MEDIATED STIMULATION OF MALIGNANT PHENOTYPES IN TUMOUR CELLS
Most studies on the Programmed Death 1 (PD-1)/Programmed Death Ligand 1 (PD-L1) immune checkpoint have focused on elucidating the signaling mechanisms leading to inactivation of immune effectors. We, along with others, have shown that signaling by the PD-1/PD-L1 immune checkpoint may be …
-
MULTIFUNCTIONAL SUPRAMOLECULAR DELIVERY SYSTEM FOR ENHANCING TUMOR IMMUNOTHERAPY
… of proteins such as antibodies against programmed death-ligand 1 (aPD-L1, atezolizumab). These engineered carriers address challenges in drug solubility, targeting, and immunotherapy. The findings highlight the potential of β-CD-based systems to revolutionize cancer immunotherapy, …
-
Immune modulation mechanisms of porcine circovirus type 2
… in vitro and evaluated for expression levels of programmed death ligand-1 (PD-L1), IL-10, CD86, swine leukocyte antigen-1 (SLA-1), and swine leukocyte antigen-2 (SLA-2). Expression levels of PD-L1 were significantly increased in PCV2 and PRRSV co-infected MoDCs. SLA-1, SLA-2, and CD86 expression …
-
NOVEL RNA-BASED CANCER VACCINE FOR AML IMMUNOTHERAPY
… key role in this. Combination therapy with anti-programmed death-ligand 1 has provided the AML mice with significant survival benefits. These data provide preclinical evidence for human study in the future.
-
Il-6/Jak1 Drives Pd-L1 Phosphorylation and Glycosylation to Promote Cancer Immune Evasion
<p>Glycosylation of immune receptors and ligands, such as T-cell receptor (TCR), major histocompatibility complex (MHC), and co-inhibitory molecules, regulates immune signaling activation, antigen presentation, and immune surveillance. Recent studies revealed that the glycan structures of …
-
Molecular mechanisms of exosome secretion
… exocyst function blocked exosomal secretion of Programmed death-ligand 1 (PD-L1), a key immune checkpoint protein in tumor cells, and led to its accumulation in lysosomes.In collaboration with the lab members, we also found that cells respond to extracellular matrix (ECM) stiffness for exosome …
-
BREAST CANCER DURING PREGNANCY AS A SPECIAL TYPE OF EARLY-ONSET BREAST CANCER: INSIGHTS INTO THE TUMOR MICROENVIRONMENT AND IMMUNE TRANSCRIPTOME
… for CD4, CD8, forkhead box P3 (FOXP3), and programmed death-ligand 1 (PD-L1) (clone 22C3). A subset of 28 PrBC and 23 EOBC was selected for transcriptome profiling. RNA extracted from tumor (T) and corresponding normal (N) tissues was subjected to gene expression analysis using a …
-
Harnessing the Immunomodulatory Potential of Radiofrequency Ablation to Improve Therapeutic Outcomes in Pancreatic Ductal Adenocarcinoma
… that when RFA is combined with an αPD-L1 (anti-programmed death-ligand 1) treatment, it causes both local and systemicimmune activation, improving Granzyme B+ cell infiltration, boosting collagen deposition, reducing immunosuppressive cytokine signaling, and promoting anabscopal response in …
-
NANOFLUIDIC ISOLATION AND QUANTIFICATION OF SPECIFIC EXTRACELLULAR VESICLES AND MACHINE LEARNING ANALYSIS TO AID CLINICAL DECISION-MAKING
… to the quantification of EVs expressing surface Programmed Death-Ligand 1 (PD-L1), in both cell culture samples and human plasma, DEVA maintained the low LOD and LOQ and agreed with gold standard method, offering potential in immunotherapy outcome prediction and melanoma prognosis. To streamline …
-
Development of Pharmaceutical Inhibitors Targeting nNOS for Melanoma Treatment
… in melanoma, has been shown to upregulate programmed death‐ligand 1 (PD‐L1) on the melanoma cell. The interaction between PD-L1 and its receptor PD-1 inactivates T-lymphocytes, allowing melanoma cells to escape from immune surveillance. Immune checkpoint inhibitors targeting PD-1/PD-L1 have …
-
Effects of nNOS Inhibitors on Melanoma-Induced Immunosuppression
… cytokine in CM, induces the expression of programmed death-ligand 1 (PD-L1), leading to the escape of melanoma cells from immunosurveillance. Our previous study suggests that neuronal nitric oxide synthase (nNOS)-mediated nitric oxide (NO) signaling is crucial for melanoma progression and …
-
Neutrophils in advanced non-small cell lung cancer
… CD8+ T cells through mechanisms including programmed death-ligand 1 (PD-L1) expression. To establish the phenotype of neutrophil populations in advanced NSCLC, neutrophils were extracted from the pleural fluid (metastatic site) and blood of patients. Cellular morphology, surface marker …
-
Targeting Neuronal Nitric Oxide Synthase (nNOS) for Melanoma Treatment
… tumor growth in a xenograft mouse model. Programmed death-ligand 1 (PD-L1) is overexpressed in melanoma and plays an important role in suppressing the immune system <sup>12-14</sup>. Our <em>in vitro</em> and <em>in vivo </em>studies show that nNOS inhibitors exhibit potent cytotoxicity to …
-
INSIGHTS ON THE CROSSTALK BETWEEN THE IMMUNE SYSTEMAND CANCER: IMMUNE CHECKPOINT MOLECULES AND LYMPHOIDPOPULATIONS ASSESSMENT IN CANINE ROUND CELL TUMORS
… (1) the expression and prognostic role of programmed death-ligand 1 (PD-L1) in canine lymphoma, (2) the expression and prognostic role of CD47 in canine leukemias, and (3) the characterization of lymphocyte populations in peripheral blood and sentinel lymph nodes (SLNs) of dogs with mast …
-
Investigating The Distinct Role of Pd-L2 In Modulating Human T Cells Responses
… Curran, Ph.D.</p> <p>Therapeutic blockade of the Programmed cell death-1 (PD-1) receptor and its ligand Programmed death ligand-1 (PD-L1) has revolutionized the treatment of multiple cancers and made durable tumor regression a possibility in the clinic. PD-1 blockade prolonged progression-free …
-
Design, synthesis, and preliminary biological evaluation of novel small molecules modulating the HuR RNA-binding protein and other therapeutically relevant targets in immuno-oncology.
… lifetime, making it the second leading cause of death in Europe and America. Many research efforts have been directed against cancer, both from pharmaceutical companies and governmental/private organizations, and several treatments are now available. Most aim to either directly kill/block the …
-
Targeting Pd-1/Pdl-1 Signaling In The Treatment of Osteosarcoma Lung Metastasis
… pulmonary metastasis, which is a major cause of death in OS patients. Novel treatments like immunotherapy hold promise for the treatment of OS pulmonary metastasis. However, immunosuppressive mechanisms such as binding of immune inhibitory receptor, PD-1 with PDL-1, which is upregulated in cancer …
-
Dissecting the Role of Hedgehog Signaling in Tumor-associated Macrophages and Immunosuppression in the Tumor Microenvironment
… to increased proliferation and metastasis. Hh ligands, including sonic hedgehog (Shh), desert hedgehog (Dhh) and indian hedgehog (Ihh) can also be secreted from tumor cells to modify the TME in order to create a more favorable environment to foster tumorigenesis. However, little is known about …
-
Altered Expression of Costimulatory Molecules in Behcet's Disease According to Clinical Activity
… T-lymphocyte antigen-4 (CTLA-4)/CD80, CD86 and programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) receptor/ligand systems are important. Also, regulatory T (Treg) cells play an important role in maintaining immune homeostasis. PURPOSE: The objective of the present study was to determine …
-
Investigating the utility of blood borne oncological biomarkers in solid tumours: glioma and melanoma
… vascular endothelial growth factor (VEGF), programmed death ligand-1 (PD-L1), interferon-gamma (IFN-γ), and tumour burden in advanced melanoma patients. Furthermore, it sought to examine whether important differences exist in the plasma transcriptomic profile of advanced melanoma patients …
Page 1 of 2